P-61 Relatlimab + nivolumab in patients with advanced hepatocellular carcinoma who are naive to immuno-oncology therapy but progressed on tyrosine kinase inhibitors, a phase 2, randomized, open-label study: RELATIVITY-073

Bruno Sangro, Kazushi Numata, Yi‐Hsiang Huang, Carlos Gómez-Martín, Atsushi Hiraoka, Michihisa Moriguchi, Ying‐Chun Shen, Andrea Horváth, William F. Feely, Tina C. Young, Jaclyn Neely, Masatoshi Kudo